139 related articles for article (PubMed ID: 18020546)
1. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Fiedler R
Clin Drug Investig; 2007; 27(12):865-6. PubMed ID: 18020546
[No Abstract] [Full Text] [Related]
2. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.
Rosery H; Bergemann R; Marx SE; Boehnke A; Melnick J; Sterz R; Williams L
Clin Drug Investig; 2006; 26(11):629-38. PubMed ID: 17163297
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
Nuijten M; Andress DL; Marx SE; Sterz R
Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
[TBL] [Abstract][Full Text] [Related]
5. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.
Hansen D; Brandi L; Rasmussen K
BMC Nephrol; 2009 Sep; 10():28. PubMed ID: 19778452
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
Menezes FG; Abreu RM; Itria A
J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
[TBL] [Abstract][Full Text] [Related]
7. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.
Manjarres L; Sanchez P; Cabezas MC; Fornasini M; Freire V; Albert A
BMC Health Serv Res; 2016 Aug; 16(1):443. PubMed ID: 27566059
[TBL] [Abstract][Full Text] [Related]
8. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model.
Nuijten M; Andress DL; Marx SE; Curry AS; Sterz R
Clin Drug Investig; 2010; 30(8):545-57. PubMed ID: 20586517
[TBL] [Abstract][Full Text] [Related]
10. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
11. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.
Hansen D; Rasmussen K; Danielsen H; Meyer-Hofmann H; Bacevicius E; Lauridsen TG; Madsen JK; Tougaard BG; Marckmann P; Thye-Roenn P; Nielsen JE; Kreiner S; Brandi L
Kidney Int; 2011 Oct; 80(8):841-50. PubMed ID: 21832979
[TBL] [Abstract][Full Text] [Related]
12. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
14. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.
Dobrez DG; Mathes A; Amdahl M; Marx SE; Melnick JZ; Sprague SM
Nephrol Dial Transplant; 2004 May; 19(5):1174-81. PubMed ID: 15004264
[TBL] [Abstract][Full Text] [Related]
15. Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients.
Lessard M; Ouimet D; Leblanc M; Nadeau-Fredette AC; Bell R; Lafrance JP; Pichette V; Vallée M
BMC Nephrol; 2014 Feb; 15():27. PubMed ID: 24495277
[TBL] [Abstract][Full Text] [Related]
16. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
[TBL] [Abstract][Full Text] [Related]
17. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients.
Bezzaoucha S; Lafrance JP; Ouimet D; Pichette V; Bell R; Lamarche C; Vallée M
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):895-6. PubMed ID: 26308178
[No Abstract] [Full Text] [Related]
20. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies.
Zhang T; Ju H; Chen H; Wen W
Ther Apher Dial; 2019 Feb; 23(1):73-79. PubMed ID: 30328270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
